Mechanistically, CDK12 inhibitors primarily exert their anticancer effects by enhancing the anti-aggregation effect in cancer cells, reducing Pol II CTD Ser2 phosphorylation to inhibit DDR gene expression, and synergizing with poly (ADP-ribose) PARPi5,14,16. The gene discussed is CDK12; the disease is cancer.